

Monoclonal Antibody (MAB) Treatment for COVID-19



What is MAB Treatment?

Generally, antibodies are proteins that people's bodies make to fight viruses, including COVID-19. Monoclonal antibodies (MABs) are made in a laboratory that act a lot like natural antibodies to limit the amount of virus in your body.

MAB treatment is for people who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments are allowed by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) while clinical studies continue to look at their usefulness and safety. Recently the FDA approved the use of monoclonal antibodies to treat certain high-risk adult and pediatric patients who have been exposed to COVID-19. This treatment method is known as post-exposure prophylaxis, or PEP.

Who can receive MAB Treatment?

Individuals that have mild to moderate COVID-19, or are a close contact with the following risk factors:

Are over the age of 65

Have other health conditions considered by their health care provider to place them at higher risk for severe illness

OR

Over the age of 12 with:

- chronic kidney disease
- heart or lung disease
- obesity
- diabetes
- pregnancy
- immunosuppressive disease

How do I get MAB Treatment?

Antibodies may be administered only in settings where health care providers have immediate access to medications to treat any reactions and where emergency medical systems are available, if needed. **Talk to your doctor or primary provider about MAB treatment if you have COVID-19 or are a close contact at high risk for severe disease or hospitalization.**